3/27/2019 7:09:53 AM
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation For AXS-05 For Major Depressive Disorder
2/6/2019 7:10:18 AM
Axsome Therapeutics Receives FDA Agreement Under SPA For MOMENTUM Phase 3 Trial Of AXS-07 In Migraine
1/30/2019 7:11:26 AM
Axsome Therapeutics Begins Phase 2 Trial Of AXS-12 In Narcolepsy; Expects Topline Results In Q2'19
1/7/2019 6:04:02 AM
Axsome Therapeutics Unveils AXS-05 Achieves Primary Endpoint In Phase 2 Trial In Major Depressive Disorder
12/10/2018 7:07:31 AM
Axsome : IDMC Recommends Continuation Of Trial Evaluating AXS-05 Versus Placebo In Alzheimer’s Disease Agitation
11/14/2018 7:10:37 AM
Axsome Therapeutics Completes Patient Enrollment In ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder
11/9/2018 7:09:19 AM
Axsome Therapeutics Q3 Net Loss $8.3 Mln Or $0.31/Shr Vs Net Loss Of $6.4 Mln Or $0.27/Shr Last Year